United Therapeutics Corporation (UTHR)
-NasdaqGS | Prev Close: | 67.82 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 55.17 |
|---|
| Beta: | 1.41 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 41.86 - 69.65 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 833,360 |
|---|
| Market Cap: | 3.37B |
|---|
| P/E (ttm): | 12.07 |
|---|
| EPS (ttm): | 5.62 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- United Reaches New 52-Week High (UTHR)at TheStreet(Wed, May 22)
- Bayer Files Riociguat in JapanZacks(Tue, May 21)
- EOG Resources CEO Sells 50K Shares and 4 Insider Sales to Noteat Wall St. Cheat Sheet(Tue, May 21)
- Innovative Therapeutic Development for Duchenne Muscular Dystrophy Moves Niche Stocks Up 300% to 400%: An Expert Portfolio Manager Discusses Investing in Health CareWall Street Transcript(Thu, May 16)
- Organovo: Get Rich Or Die Tryin'at Seeking Alpha(Wed, May 15)
- United Therapeutics downgraded by Standpoint ResearchBriefing.com(Wed, May 15)
- United Stock Hits New 52-Week High (UTHR)at TheStreet(Tue, May 14)
- Gilead Shows Some Heartat Motley Fool(Wed, May 8)
- Industry Ranks May 2013at Seeking Alpha(Mon, May 6)
- Three Mid-Cap Stocks To Keep An Eye Onat Motley Fool(Thu, May 2)
- Alternative Generic Drug Products to Sustain Decent Margins and Cash Flow Generation Over the Long Term: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street TranscriptWall Street Transcript(Thu, May 2)
- United Rises On Unusually High Volume (UTHR)at TheStreet(Tue, Apr 30)
- Indexes Recover Early Losses As Turnover Picks Upat Investor's Business Daily(Tue, Apr 30)
- UNITED THERAPEUTICS CORP FinancialsEDGAR Online Financials(Tue, Apr 30)
- United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapyat Seeking Alpha(Tue, Apr 30)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| UTHR | 0.00% | 3.37B |
| NVO | 0.00% | 91.83B |
| TEVA | 0.00% | 33.53B |
| AGN | 0.00% | 28.97B |
| FRX | 0.00% | 9.99B |
Key Statistics
| Forward P/E (1 yr): | 9.53 |
|---|
| P/S (ttm): | 3.53 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 6.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.47 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | 0.28 |
|---|
Business Summary
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide.
View More